Business Context and Reporting Period
Company: Astro-Med, Inc. (Note: Input metadata referenced "Astronova, Inc.", but the filing text identifies the registrant as Astro-Med, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended August 3, 2002.
Business Overview: The company operates in three reporting segments: Test & Measurement (T&M), QuickLabel Systems (QLS), and Grass-Telefactor (G-T). The company manufactures and sells products for test and measurement, specialty printing, and biomedical applications.
Key Financial Metrics
| Metric | Three Months Ended Aug 3, 2002 |
Six Months Ended Aug 3, 2002 |
|---|---|---|
| Net Sales | $12,922,466 | $24,304,271 |
| Gross Profit | $4,854,695 | $8,664,116 |
| Gross Margin | 37.6% | 35.6% |
| Operating Income (Loss) | $40,837 | $(899,601) |
| Net Income (Loss) | $156,142 | $(476,532) |
| EPS (Basic) | $0.04 | $(0.11) |
| Cash and Equivalents | $3,562,561 | $3,562,561 (End of Period) |
| Operating Cash Flow | N/A | $1,428,244 |
| Current Liabilities | $5,459,299 | $5,459,299 (End of Period) |
Material Changes vs. Prior Period
- Revenue: Three-month sales increased 7% to $12.9 million compared to the prior year. Six-month sales decreased 1% to $24.3 million.
- Profitability: The company reported a net income of $156,142 for the quarter, a turnaround from a net loss of $194,058 in the same period last year. However, the six-month period resulted in a net loss of $476,532, widening from a $44,394 loss in the prior year.
- Margins: Gross margin declined to 37.6% (quarter) and 35.6% (six months) from 39.3% and 40.0% respectively in the prior year, attributed to changes in sales mix.
- Expenses: Selling, General, and Administrative (SG&A) expenses decreased 7% in the quarter and 8% in the six-month period, driven by personnel reductions, lower advertising/travel, and the elimination of goodwill amortization.
- Segment Performance:
- T&M: Sales up 12% (quarter) and flat (six months); margins improved.
- QLS: Sales up 18% (quarter) and 13% (six months); margins improved in the quarter but declined for the six-month period.
- G-T: Sales down 10% (quarter) and 17% (six months) due to lower long-term monitoring sales and reduced research spending; margins improved in the quarter but declined for the six-month period.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted improved accounts receivable collection (down to 52 days from 60) and better inventory control (turns improved to 2.9 times). The company paid cash dividends of $0.08 per share for the six-month period.
Risks and Contingencies:
- Market Risks: Declining demand in defense and aerospace test and measurement markets; competition in specialty printing and neurophysiology industries.
- Operational Risks: Ability to gain market acceptance for new QLS color printer products; impact of foreign currency exchange rates.
- Auditor Change: The company dismissed Arthur Andersen LLP on June 28, 2002, and engaged Ernst & Young as the new independent auditor on July 9, 2002.
Forward-Looking Statements: The filing includes a Safe Harbor statement noting that actual results may differ due to economic conditions, competition, and integration of acquisitions.
Investor Verification Checklist
- Auditor Transition: Verify the status of the audit transition from Arthur Andersen to Ernst & Young and any potential impact on future financial reporting.
- Segment Mix: Analyze the sustainability of the sales mix shift that caused gross margin compression, particularly in the G-T and QLS segments.
- Defense Spending: Monitor the impact of shifting defense spending (from testing/research to counter-terrorism) on the T&M segment's Everest product line.
- Liquidity: Confirm the trend in working capital improvements (receivables and inventory) continues in subsequent quarters.
- Dividend Policy: Assess the company's ability to maintain dividend payments given the six-month net loss.